Gaudium IVF & Women Health Limited has provided additional disclosures to stock exchanges regarding the arbitration proceedings filed against the company by Neomile Corporate Advisory Limited, following a query from BSE Limited seeking clarification on the ₹29,20,50,000 claim for alleged advisory services related to its Initial Public Offering.

BSE Query and Company Response

Following the company's initial disclosure on April 06, 2026, BSE Limited raised a query on April 07, 2026, seeking additional details in terms of SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company has now submitted the required comprehensive disclosures under Regulation 30 of SEBI Listing Regulations.

Court Proceedings Update

The Bombay High Court has disposed of the Commercial Arbitration Petition under Section 9 of the Arbitration and Conciliation Act, 1996, and appointed Hon'ble Mr. Justice Nitin Jamdar (Former Chief Justice, Kerala High Court) as the Sole Arbitrator to adjudicate upon the dispute. The court order was issued on April 02, 2026.

Disclosure Timeline Explanation

The company has provided a detailed explanation for the timing of its disclosure. The court order was uploaded on the court's official website on Saturday, April 04, 2026, in the late evening. The company became aware of the order on April 06, 2026, being the next working day, and made the intimation within 24 hours of receiving the order.

Key Parties Involved

Along with the company, Dr. Manika Khanna, Chairperson and Managing Director and Promoter of Gaudium IVF, is also a party to the arbitration proceedings. The opposing party, Neomile Corporate Advisory Limited, is seeking ₹29,20,50,000 (inclusive of GST) for alleged IPO advisory services.

Regulatory Compliance

The enhanced disclosure was signed by Company Secretary Naveen Kumar (Membership No: A69788) and submitted to both BSE Limited (Scrip Code – 544709) and National Stock Exchange of India Limited (Symbol – GAUDIUMIVF). The information has also been placed on the company's official website as required by regulatory guidelines.

Gaudium IVF & Women Health has announced a groundbreaking development in India's fertility healthcare sector with the introduction of artificial intelligence-led infertility treatment. This milestone represents an industry first in the country, coming just one month after the company became India's first publicly listed IVF chain.

AI-Driven Technology Integration

The development involves the integration of advanced AI-driven embryology systems into routine clinical practice. The company has introduced two key technologies:

The milestone was formally inaugurated by Hon'ble Union Minister Shri Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India, on April 1st, 2026.

Strategic Partnership with IVF 2.0

This integration has been undertaken in collaboration with IVF 2.0, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. The partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.

Giles Palmer, Clinical Scientist and Director of Global Communications at IVF 2.0, stated: "Our focus has always been to translate embryology intelligence into measurable clinical outcomes. Partnering with Gaudium IVF allows us to bring our AI-driven solutions into a high-growth market like India and set new benchmarks for how reproductive medicine is practised."

Technology Capabilities and Clinical Impact

The newly introduced technologies are designed to enhance critical stages of the IVF process:

SiD (Sperm Identification Device) analyses various sperm movement parameters to identify the most viable sperm for fertilisation, potentially leading to better-quality blastocyst formation.

ERICA (Embryo Ranking Intelligent Classification Assistant) provides objective, data-driven ranking of embryos by analysing static images of blastocysts based on key morphological and developmental characteristics.

These non-invasive tools assist embryologists in improving decision-making and reducing variability. Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates.

Leadership Perspectives

Hon'ble Union Minister Shri Nitin Jairam Gadkari remarked at the inauguration: "The adoption of advanced technologies such as artificial intelligence reflects India's growing strength in innovation. Initiatives like these will play an important role in shaping the future of technology-led solutions across sectors."

Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF, commented: "Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey."

Expected Benefits

By improving precision and consistency, the adoption of AI has the potential to:

• Reduce the need for repeat cycles
• Lower the emotional, physical, and financial burden on patients
• Inspire confidence among clinicians and stakeholders
• Enhance overall treatment success rates

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility care provider with a PAN India presence and growing global reach. The organisation continues to push the boundaries of reproductive healthcare innovation in the country, reinforcing its position as an industry pioneer under the leadership of Manika Khanna.